Company: DMAAR
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001213900-25-076681
Chunk: 33

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 33
---

statements, please refer to the “Risk Factors” section of the Company’s final prospectus for its initial public offering
filed with the U.S. Securities and Exchange Commission (the “SEC”). The Company’s filings with the SEC can be accessed
on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, the Company
disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future
events or otherwise.

Overview

We are a blank check company incorporated in the
Cayman Islands on May 23, 2024 formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization,
reorganization or other similar business combination with one or more businesses. We intend to effectuate our initial business combination
using cash derived from the proceeds of the Initial Public Offering (as defined below) and the sale of the Private Placement Units (as
defined below), our shares, debt or a combination of cash, shares and debt.

We expect to continue to incur significant costs
in the pursuit of our acquisition plans. We cannot assure you that our plans to complete an initial business combination will be successful.

While we may pursue a business combination target
in any business, industry or geographical location, we intend to focus our search for businesses in the pharmaceutical industry. The Company
is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and
emerging growth companies.

The registration statement for the Company’s
initial public offering (the “IPO” or “Initial Public Offering”) was declared effective on January 27, 2025. On
January 29, 2025, we consummated our Initial Public Offering of 20,000,000 units (the “Units”). Each Unit consists of one
ordinary share, $0.0001 par value (“ordinary share”) and one right to receive one-eighth (1/8) of one ordinary share upon
the consummation of an initial business combination. The Units were sold at an offering price of $10.00 per unit, generating gross proceeds,
before expenses, of $200,000,000. We granted the underwriters a 45-day option to purchase up to 3,000,000 additional Units to cover over-allotments,
if any.

19

Simultaneously with the closing of the IPO